Navigation Links
Governor Gregoire and Congressman McDermott Join Novo Nordisk at Opening Event for Type 1 Diabetes Research Center in Seattle

SEATTLE, June 13, 2012 /PRNewswire/ -- Novo Nordisk (NYSE: NVO) hosted a community event today to celebrate the official opening of Novo Nordisk's new type 1 Diabetes R&D Center in Seattle, which will explore innovative approaches to treat and prevent type 1 diabetes.

(Logo: )

Novo Nordisk, a leader in diabetes care, is the largest global manufacturer of insulin. The new center will combine Novo Nordisk's longstanding history of innovation and diabetes treatment with the company's growing expertise in immunotherapy.

The event featured a keynote address from Governor Chris Gregoire, as well as remarks from Congressman Jim McDermott (WA-7), Novo Nordisk's Senior Leadership, key community leaders, and local diabetes patients. 

"This new research facility represents hope for everyone affected by type 1 diabetes," said Gov. Gregoire. "Developing better treatments for this chronic and costly disease – and the possibility of even finding a cure – is a critically important mission as the number of people with type 1 diabetes continues to increase. The State of Washington looks forward to the innovation that will take place here in close collaboration with the local and national research communities in type 1 diabetes."

The unique concept behind the new center is to pursue a translational research approach characterized by combining basic research and early proof-of-concept trials under one umbrella. This integrated research approach provides the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinical exploratory trials in type 1 diabetes.

Novo Nordisk was drawn to Seattle because of its strong reputation for public-private scientific collaboration and the talented biotech researchers who work here.

"The diabetes R&D center is a welcome addition to the City of Seattle. The opening of this facility will represent 20 new jobs for our scientific community and an opportunity to showcase Seattle's biotech hub," remarked Rep. McDermott.

The opening of this center will re-focus efforts on type 1 diabetes, a condition that has lacked major scientific progress in recent years. In the past decade, type 2 diabetes has been the main focus among diabetes researchers and pharmaceutical companies because of the dramatic rise in the number of people living with the disease. Type 1 diabetes is a different disease that requires life-saving treatment with insulin.

"This center will provide opportunities to accelerate our researchers' best ideas and make real progress in bringing treatment advances to people with type 1 diabetes," said Matthias von Herrath, MD, a world-renowned researcher in auto-immune diseases and head of the new Novo Nordisk diabetes research center. "We are driven by the company's mandate to find a cure for type 1 diabetes – something that is unique for the pharmaceutical industry today."

The new center, which will be fully operational this summer, is located on the same premises as the Novo Nordisk Inflammation Research Center in order to foster natural research synergies between the two sites.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit  For more information about our US activities, follow us on Twitter at @novonordiskus.

SOURCE Novo Nordisk
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chesapeake Urologys Dr. Brad Lerner, Chief of Urology at Union Memorial Hospital, Honored with Governors Citation for Outstanding Service
2. Phonak and Special Olympics join forces with US Olympian, former Congressman Jim Ryun
3. PAREXEL Chairman And CEO To Ring The Bell At The NASDAQ Stock Market Opening
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Global Pharmaceutical Leaders All Converging in Parsippany, New Jersey on September 11-12, 2012 for Breakthrough Event
7. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
8. Physician-Patient Alliance for Health & Safety: Monitoring Technology for PCA Pumps Can Prevent Adverse Events: So Why Are Hospitals Not Using It?
9. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
10. New Study Shows Long-Term Effects of Drug Prevention
11. Simbionix Releases Two New Platforms at the Upcoming DDW and AUA Events
Post Your Comments:
(Date:11/25/2015)... 25, 2015 Endo International plc (NASDAQ: ENDP ... , President and CEO, will discuss corporate updates at the ... New York on Wednesday, December 2, 2015 ... on Investor Relations, and then the link to the event. ... start time to visit the site and download any streaming ...
(Date:11/25/2015)... 2015 Asia -based ... BioLight and the New Investors will make a direct ... a private placement. The financing will help IOPtima to ... used in the treatment of glaucoma, as well as ... IOPtimate™ system with the U.S. Food and Drug Administration, ...
(Date:11/25/2015)... 2015 - Will Also Offer ... (CME) --> - Will Also ... (CME) --> - Will ... Medical Education (CME) Elsevier , a ... will feature latest diagnostic imaging textbooks and decision support tools, as ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... “While riding the bus, I saw a passenger in a wheelchair drenched ... be a convenient and comfortable way to protect them from bad weather, so I ... travel during cold or inclement weather. In doing so, it ensures that the user ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
(Date:11/24/2015)... Mississauga, ON (PRWEB) , ... November 24, 2015 , ... ... Deborah Williams without a referral for dental implants at her Mississauga, ON ... qualified and experienced in the placement of dental implants. , Missing teeth can ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced that ... Clinical Trial Supply East Asia Conference, to be held at the InterContinental Seoul ...
Breaking Medicine News(10 mins):